Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies.

about

Genetic variation in the dopamine pathway and smoking cessation.

P2860

Q37264547-6DD552C2-ADC4-48E7-8AFB-98CF4B1BD2C8

P2860

Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies.

Item

http://www.wikidata.org/entity/Q36966043

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

2007年论文

@zh

2007年论文

@zh-cn

name

Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies.

@en

type

Item

label

Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies.

@en

prefLabel

Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies.

@en

P1476

Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies.

@en

P2093

Raju Kucherlapati

http://www.w3.org/2001/XMLSchema#string

Victoria A Joshi

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

P304

1211-1220

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/14622416.8.9.1211

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2007-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17924836

http://www.w3.org/2001/XMLSchema#string

P921

pharmacogenomics

Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies.

about

P2860

P2860

Pharmacogenomics of lung cancer: with a view to address EGFR-targeted therapies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921